New 'shock and kill' therapy aims to flush out and destroy hidden HIV
NCT ID NCT07577986
First seen May 12, 2026 · Last updated May 16, 2026 · Updated 2 times
Summary
This study tests a two-step approach to target hidden HIV in the body. First, a drug called chidamide wakes up dormant HIV-infected cells. Then, specially designed natural killer (NK) cells are infused to find and kill those cells. The trial involves 20 adults with HIV who are stable on antiretroviral therapy. The main goal is to check safety, but researchers will also look for signs that the hidden HIV reservoir is shrinking.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV - HUMAN IMMUNODEFICIENCY VIRUS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
the first affiliated hospital of Zhejiang university school of medicine, Hangzhou, Zhejiang 310000
Hangzhou, Zhejiang, 310000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.